EMBARGOED FOR RELEASE: 3 P.M. (CT), WEDNESDAY, JUNE 11, 2014
Media Advisory: To contact author Kimberly Ann Yonkers, M.D., call William Hathaway at 203-432-1322 or email email@example.com.
Bottom Line: Diagnoses of both posttraumatic stress disorder (PTSD) and a major depressive episode appear to be associated with a sizable increase in risk for preterm birth that seems to be independent of antidepressant and benzodiazepine medication use.
Authors: Kimberly Ann Yonkers, M.D., of the Yale School of Medicine, New Haven, Conn., and colleagues.
Background: Preterm birth is responsible for many infant deaths. Clinicians and patients are concerned about the risks associated with psychiatric illness during pregnancy and the medications used for treatment.
How the Study Was Conducted: The study included a group of 2,654 pregnant women recruited before 17 weeks gestation. The authors looked for PTSD, major depressive episode, and the use of antidepressant and benzodiazepine medications. They measured preterm births, defined as birth before 37 weeks gestation.
Results: Of the women, 129 (4.9 percent) had symptoms consistent with PTSD. Pregnant women with both PTSD and a major depressive episode had a four-fold increased risk of preterm birth. Each one-point increase on a scale measuring PTSD symptoms increased the risk for preterm birth by 1 percent to 2 percent. Women prescribed serotonin reuptake inhibitor and benzodiazepine medications had higher odds for preterm birth.
Discussion: “The risk appears independent of antidepressant or benzodiazepine use and is not simply a function of mood or anxiety symptoms. Further exploration of the biological and genetic factors will help risk-stratify patients and illuminate the pathways leading to this risk.”
(JAMA Psychiatry. Published online June 11, 2014. doi:10.1001/jamapsychiatry.2014.558. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: Authors made conflict of interest disclosures. This study was supported by a National Institute of Child Health and Human Development grant. Authors also made grant support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email firstname.lastname@example.org.